June 11, 2021
During the 2021 ASCO Annual Meeting, Know AML spoke with Chris Hourigan, National Institutes of Health, Bethesda, US. We asked, How can we detect AML earlier? Hourigan explains how to treat patients who initially respond to treatment (remission) but later have detectable leukemia again (relapse). He then explains how we can use better techniques to detect low amounts of disease in patients in remission, known as measurable residual disease (MRD). Finally, he explains the next stage of predicting patients at high risk of developing AML.